HRP20120712T1 - Postupak zarastanja rana primjenom antagonista adenozinskog a2b receptora - Google Patents

Postupak zarastanja rana primjenom antagonista adenozinskog a2b receptora Download PDF

Info

Publication number
HRP20120712T1
HRP20120712T1 HRP20120712TT HRP20120712T HRP20120712T1 HR P20120712 T1 HRP20120712 T1 HR P20120712T1 HR P20120712T T HRP20120712T T HR P20120712TT HR P20120712 T HRP20120712 T HR P20120712T HR P20120712 T1 HRP20120712 T1 HR P20120712T1
Authority
HR
Croatia
Prior art keywords
optionally substituted
propyl
dione
methyl
trihydropurine
Prior art date
Application number
HRP20120712TT
Other languages
English (en)
Croatian (hr)
Inventor
Dewan Zeng
Luiz Belardinelli
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of HRP20120712T1 publication Critical patent/HRP20120712T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HRP20120712TT 2004-09-01 2005-08-30 Postupak zarastanja rana primjenom antagonista adenozinskog a2b receptora HRP20120712T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20120712T1 true HRP20120712T1 (hr) 2012-10-31

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120712TT HRP20120712T1 (hr) 2004-09-01 2005-08-30 Postupak zarastanja rana primjenom antagonista adenozinskog a2b receptora

Country Status (21)

Country Link
US (1) US20060058322A1 (enExample)
EP (1) EP1789053B1 (enExample)
JP (2) JP4929173B2 (enExample)
KR (1) KR101247528B1 (enExample)
CN (1) CN101043889B (enExample)
AU (1) AU2005282860B2 (enExample)
CA (1) CA2578702A1 (enExample)
DK (1) DK1789053T3 (enExample)
ES (1) ES2387653T3 (enExample)
HR (1) HRP20120712T1 (enExample)
IL (1) IL181634A (enExample)
MX (1) MX2007002437A (enExample)
NO (1) NO20071718L (enExample)
NZ (1) NZ553487A (enExample)
PL (1) PL1789053T3 (enExample)
PT (1) PT1789053E (enExample)
RS (1) RS52455B (enExample)
RU (1) RU2385322C2 (enExample)
SI (1) SI1789053T1 (enExample)
WO (1) WO2006028810A2 (enExample)
ZA (1) ZA200701777B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2357969C2 (ru) 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
CA3093234A1 (en) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
US20230365564A1 (en) * 2020-09-04 2023-11-16 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
CA2400206A1 (en) * 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
RU2318824C2 (ru) * 2001-11-09 2008-03-10 Си Ви Терапьютикс, Инк. Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists

Also Published As

Publication number Publication date
NZ553487A (en) 2010-09-30
RU2007107605A (ru) 2008-09-10
DK1789053T3 (da) 2012-08-06
MX2007002437A (es) 2007-08-14
CA2578702A1 (en) 2006-03-16
HK1107261A1 (en) 2008-04-03
JP4929173B2 (ja) 2012-05-09
IL181634A0 (en) 2007-07-04
RS52455B (sr) 2013-02-28
ES2387653T3 (es) 2012-09-27
CN101043889B (zh) 2010-11-03
WO2006028810A2 (en) 2006-03-16
US20060058322A1 (en) 2006-03-16
EP1789053A2 (en) 2007-05-30
IL181634A (en) 2015-05-31
PT1789053E (pt) 2012-08-09
AU2005282860B2 (en) 2012-03-22
CN101043889A (zh) 2007-09-26
KR101247528B1 (ko) 2013-04-15
RU2385322C2 (ru) 2010-03-27
WO2006028810A3 (en) 2006-09-28
ZA200701777B (en) 2008-09-25
SI1789053T1 (sl) 2012-09-28
NO20071718L (no) 2007-03-30
AU2005282860A1 (en) 2006-03-16
KR20070047816A (ko) 2007-05-07
PL1789053T3 (pl) 2012-12-31
JP2008511654A (ja) 2008-04-17
JP2011246492A (ja) 2011-12-08
EP1789053B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
RU2007117907A (ru) Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
HRP20120712T1 (hr) Postupak zarastanja rana primjenom antagonista adenozinskog a2b receptora
CA2466477A1 (en) A2b adenosine receptor antagonists
JP2008516969A5 (enExample)
ES2806135T3 (es) Nuevos inhibidores de bromodominios bicíclicos
US7919488B2 (en) Therapeutic compounds
JP5281287B2 (ja) ヘテロ環置換ベンズイミダゾール誘導体
JP6496731B2 (ja) Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
JP2005509036A5 (enExample)
JP2021120403A (ja) 一過性受容体電位ａ１イオンチャネルの阻害
JP2004517848A (ja) 抗ウイルス剤
US7317017B2 (en) A2B adenosine receptor antagonists
JP2009544742A5 (enExample)
JP2008511654A5 (enExample)
JP2003502418A (ja) 抗ウイルス剤
US20130172333A1 (en) Formulation and dosing of hsp90 inhibitory compounds
JP2018534328A5 (enExample)
TW201139436A (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AU2018367193A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
CA2934108A1 (en) Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
KR20040095288A (ko) 파레콕시브 나트륨 결정체
KR20090031721A (ko) 염증성 장 질환의 처치제
JP2013533882A5 (enExample)
US8569504B2 (en) Imidazopyridine compound
RU2013148009A (ru) Алкалоидный эфир и карбаматные производные и их медицинские композиции